Since the initiation and progression of NAFLD/NASH is a slow and progressive process, applying an appropriate therapy that can target most of its crucial pathological events (e.g., insulin resistance, lipid accumulation, inflammation and fibrosis), should theoretically prevent or reverse the process of NASH to a nearly healthy condition [6,7]. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.